Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC) : retrospective multicentric analysis of post-progression treatments
Copyright © 2023 Elsevier Ltd. All rights reserved..
INTRODUCTION: Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi). As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap. In patients with a gBRCA-PV and advanced BC (aBC), it remains unclear whether prior exposure to PARPi/PBC affects tumour response to subsequent PBC/PARPi, respectively.
METHODS: We conducted a retrospective, multicentric study to investigate the clinical benefit of post-PBC PARPi and vice versa in patients with a gBRCA-PV and aBC. Patients included had received (neo)adjuvant PBC and then PARPi in advanced setting (group 1), PBC followed by PARPi (group 2) or PARPi followed by PBC (group 3), both in advanced setting. We reported median progression-free survival (mPFS) and disease control rate (DCR) in each group.
RESULTS: A total of 67 patients from six centres were included. PARPi-mPFS in advanced setting was 6.1 months in patients in group 1 (N = 12), while PARPi-DCR was 67%. In group 2 (N = 36), PARPi-mPFS was 3.4 months and PARPi-DCR was 64%. Age < 65 years and platinum-free interval (PFI) > 6 months were associated with longer PARPi-PFS; previous PBC-PFS > 6 months and PBC in first to second line were associated with longer PARPi-DCR. Patients in group 3 (N = 21) reported a PBC-mPFS of 1.8 months and a PBC-DCR of 14%. PARPi-PFS ≥ 9 months and PARPi-FI ≥ 6 months were associated with better PBC-DCR.
CONCLUSIONS: Sensitivity and resistance to PARPi and PBC partially overlap in patients with a gBRCA-PV and aBC. Evidence of PARPi activity emerged in patients who progressed on previous PBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 190(2023) vom: 01. Sept., Seite 112944 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Valenza, Carmine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 09.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2023.112944 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359381790 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359381790 | ||
| 003 | DE-627 | ||
| 005 | 20231226080741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.112944 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359381790 | ||
| 035 | |a (NLM)37437366 | ||
| 035 | |a (PII)S0959-8049(23)00296-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Valenza, Carmine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC) |b retrospective multicentric analysis of post-progression treatments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 09.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi). As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap. In patients with a gBRCA-PV and advanced BC (aBC), it remains unclear whether prior exposure to PARPi/PBC affects tumour response to subsequent PBC/PARPi, respectively | ||
| 520 | |a METHODS: We conducted a retrospective, multicentric study to investigate the clinical benefit of post-PBC PARPi and vice versa in patients with a gBRCA-PV and aBC. Patients included had received (neo)adjuvant PBC and then PARPi in advanced setting (group 1), PBC followed by PARPi (group 2) or PARPi followed by PBC (group 3), both in advanced setting. We reported median progression-free survival (mPFS) and disease control rate (DCR) in each group | ||
| 520 | |a RESULTS: A total of 67 patients from six centres were included. PARPi-mPFS in advanced setting was 6.1 months in patients in group 1 (N = 12), while PARPi-DCR was 67%. In group 2 (N = 36), PARPi-mPFS was 3.4 months and PARPi-DCR was 64%. Age < 65 years and platinum-free interval (PFI) > 6 months were associated with longer PARPi-PFS; previous PBC-PFS > 6 months and PBC in first to second line were associated with longer PARPi-DCR. Patients in group 3 (N = 21) reported a PBC-mPFS of 1.8 months and a PBC-DCR of 14%. PARPi-PFS ≥ 9 months and PARPi-FI ≥ 6 months were associated with better PBC-DCR | ||
| 520 | |a CONCLUSIONS: Sensitivity and resistance to PARPi and PBC partially overlap in patients with a gBRCA-PV and aBC. Evidence of PARPi activity emerged in patients who progressed on previous PBC | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Advanced breast cancer | |
| 650 | 4 | |a Germline BRCA pathogenic variants | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a Platinum-based chemotherapy | |
| 650 | 4 | |a Predictive factors | |
| 650 | 4 | |a Resistance | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Trapani, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Gandini, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Sposetti, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Boscolo Bielo, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Giarratano, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Favero, Diletta |e verfasserin |4 aut | |
| 700 | 1 | |a Cortesi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Moscetti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Pistelli, Mirco |e verfasserin |4 aut | |
| 700 | 1 | |a Berardi, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Zambelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Vernieri, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 190(2023) vom: 01. Sept., Seite 112944 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2023 |g day:01 |g month:09 |g pages:112944 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2023.112944 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2023 |b 01 |c 09 |h 112944 | ||